이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty

2026년 5월 13일 업데이트: Nick Hernandez, University of Washington

Doxepin Versus Doxepin and Ramelteon Versus Placebo to Improve Sleep Quality After Primary Total Knee Arthroplasty: A Randomized Controlled Trial

Many patients experience poor sleep during recovery after total knee arthroplasty (TKA). Disturbed sleep can last weeks to months and may worsen pain, slow healing, and reduce overall quality of life. Few safe, effective, evidence-based options exist to improve sleep during this recovery period. This study aims to determine whether the medications doxepin, either alone or in combination with ramelteon, can improve sleep quality during early recovery after TKA. The investigators will also evaluate whether improved sleep leads to better pain control, knee function, and overall quality of life.

연구 개요

상세 설명

This randomized, placebo-controlled clinical trial seeks to answer the following question: Is doxepin or combination therapy consisting of doxepin plus ramelteon superior to placebo in terms of (1) sleep quality as measured by the Insomnia Severity Index, (2) postoperative knee function as measured by KOOS-JR, KOOS-PS, or (3) overall health-related quality of life during the first three months after total knee arthroplasty.

연구 유형

중재적

등록 (추정된)

129

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Gerald Y Liao, MS
  • 전화번호: 617-710-7211
  • 이메일: liaog@uw.edu

연구 연락처 백업

  • 이름: Nicholas M Hernandez, MD
  • 전화번호: 530-514-1275
  • 이메일: nichern@uw.edu

연구 장소

    • Washington
      • Seattle, Washington, 미국, 98133
        • University of Washington Medical Center Hip & Knee Center
        • 연락하다:
        • 수석 연구원:
          • Nicholas M Hernandez, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Those receiving primary total knee arthroplasty (TKA)
  • 80 years or less, age 18 or greater

Exclusion Criteria:

  • History of cardiovascular bundle branch block
  • Actively taking selecrtive serotoin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or having treatment via counseling/psychotherapy for major depression or anxiety, bipolar, or psychotic disorder
  • Pre-operative narcotics (defined as more than 1 prescription in the past 3 months)
  • Self-reported use of alcohol in excess of >2 drinks/day (in men) and > 1 drink/day (in women)
  • Use of prescription sleep aids (e.g., Ambien, Trazadone) prior to surgery (i.e., melatonin or other OTC sleep aids are permitted)
  • History of major sleep disorder (e.g., obstructive sleep apnea (OSA), restless leg syndrome, narcolepsy)
  • Pregnant, breastfeeding or planning to become pregnant in the next 3 months post-surgery. No pregnancy testing will be performed; screening will rely solely on participant self-report.
  • Unable to take the study medication(s) due to contraindications with other medications the patient uses
  • Have been diagnosed with (or are at risk of) narrow-angle or angle-closure glaucoma. In order to be eligible, participants must be able to report that they have had their eyes dilated within the past year without problems.
  • Have severe urinary retention or difficulty emptying your bladder.
  • Had glaucoma-related eye procedures (e.g., laser iridotomy)
  • Ongoing use of glaucoma eye drops.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Doxepin 6 mg
Participants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
실험적: Doxepin 6 mg and Ramelteon 8mg
Participants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Ramelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
위약 비교기: Placebo
Participants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
Placebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Insomnia Severity Index (ISI) scores (sleep quality)
기간: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Insomnia Severity Index (ISI) The Insomnia Severity Index is a 7-item self-reported questionnaire assessing the nature, severity, and impact of insomnia.

  • Score range: 0 to 28
  • Interpretation: Higher scores indicate worse insomnia severity

Score categories:

  • 0-7: No clinically significant insomnia
  • 8-14: Subthreshold insomnia
  • 15-21: Clinical insomnia (moderate severity)
  • 22-28: Clinical insomnia (severe)
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

2차 결과 측정

결과 측정
측정값 설명
기간
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS)
기간: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.

Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS):

The KOOS-PS is a 7-item patient-reported outcome measure assessing knee-related physical function, including activities such as rising from bed, putting on socks, rising from sitting, bending to the floor, twisting/pivoting, kneeling, and squatting . Each item is scored on a 5-point Likert scale (None to Extreme). Scores are transformed to a normalized scale ranging from 0 to 100, with higher scores indicating worse physical function (greater disability).

Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR)
기간: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR):

The KOOS-JR is a patient-reported outcome measure assessing knee pain, stiffness, and functional limitations during activities of daily living over the past week, including tasks such as twisting/pivoting, stair navigation, standing, rising from sitting, and bending . The instrument consists of 7 items scored on a 5-point Likert scale (None to Extreme). Raw scores (range 0-28) are summed and converted to an interval score ranging from 0 to 100, where 0 represents total knee disability and 100 represents perfect knee health (higher scores indicate better outcomes)

Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10)
기간: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10):

The PROMIS-10 is a 10-item patient-reported outcome measure assessing global physical health, mental health, pain, fatigue, and social functioning. Items are scored on 5-point Likert scales (e.g., Excellent to Poor; Not at all to Very much), with one pain item scored from 0 to 10. Raw scores are summed and converted to standardized T-scores for Global Physical Health and Global Mental Health, each ranging approximately from 0 to 100 (mean 50, standard deviation 10), where higher scores indicate better health status

Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

기타 결과 측정

결과 측정
측정값 설명
기간
90-Day Hospital Readmission Status
기간: Within 90 days postoperatively
Hospital readmission status within 90 days following primary total knee arthroplasty, defined as any unplanned inpatient admission to a hospital occurring within 90 days after the index procedure. This is a dichotomous outcome (Yes/No), where "Yes" indicates that a readmission occurred and represents a worse outcome.
Within 90 days postoperatively
Medication Compliance
기간: 2 weeks postoperatively; 6 weeks postoperatively

Medication Compliance:

Medication adherence assessed using patient self-report and pill counts when feasible. Self-reported adherence is measured by patient-reported proportion of prescribed doses taken, and pill counts are used to calculate the percentage of medication consumed relative to the prescribed amount. Adherence is expressed as a percentage from 0 to 100%, where higher values indicate better compliance.

2 weeks postoperatively; 6 weeks postoperatively
Length of Stay (LOS)
기간: Perioperative/Periprocedural

Length of Stay (LOS):

Length of hospital stay following primary total knee arthroplasty, defined as the number of days from hospital admission to discharge (continuous variable, ≥0 days), where higher values indicate longer hospitalization (worse outcome).

Perioperative/Periprocedural
Discharge Destination
기간: Perioperative/Periprocedural

Discharge Destination:

Discharge disposition following primary total knee arthroplasty, categorized as home versus skilled nursing facility. This is a categorical outcome where discharge to a skilled nursing facility represents a worse outcome compared to discharge home.

Perioperative/Periprocedural
Postoperative Mobility (Step Count)
기간: Perioperative/Periprocedural

Postoperative Mobility (Step Count):

Postoperative mobility assessed by the number of steps taken during inpatient physical therapy sessions following primary total knee arthroplasty. Step count is recorded as the total number of steps ambulated (continuous variable, ≥0), where higher values indicate better functional recovery.

Perioperative/Periprocedural
Level of Assistance Required for Ambulation
기간: Perioperative/Periprocedural

Level of Assistance Required for Ambulation:

Level of assistance required during inpatient physical therapy following primary total knee arthroplasty, categorized as independent, 1-person assist, 2-person assist, or maximal assist. This is an ordinal outcome where greater assistance requirements indicate worse functional recovery.

Perioperative/Periprocedural
Postoperative Falls
기간: Perioperative/Periprocedural; 3 months postoperatively
Postoperative Falls: Occurrence of patient falls during hospitalization or within the follow-up period after primary total knee arthroplasty, defined as any unintentional descent to the ground or lower level documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a fall occurred and represents a worse outcome.
Perioperative/Periprocedural; 3 months postoperatively
Postoperative Delirium
기간: Perioperative/Periprocedural; 3 months postoperatively
Occurrence of delirium during hospitalization or follow-up after primary total knee arthroplasty, defined by clinical documentation of acute confusional state or use of delirium-related precautions (e.g., 1:1 sitter, physical restraints). This is a dichotomous outcome (Yes/No), where "Yes" indicates delirium occurred and represents a worse outcome.
Perioperative/Periprocedural; 3 months postoperatively
Pressure Ulcers (Bed Sores)
기간: Perioperative/Periprocedural; 3 months postoperatively

Pressure Ulcers (Bed Sores):

Development of pressure ulcers during hospitalization or follow-up after primary total knee arthroplasty, defined as localized injury to the skin or underlying tissue documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a pressure ulcer occurred and represents a worse outcome.

Perioperative/Periprocedural; 3 months postoperatively
Postoperative Opioid Consumption (Morphine Milligram Equivalents)
기간: Perioperative/Periprocedural; 3 months postoperatively

Postoperative Opioid Consumption (Morphine Milligram Equivalents):

Total postoperative opioid use following primary total knee arthroplasty, calculated as cumulative morphine milligram equivalents (MME) administered during hospitalization and follow-up. This is a continuous variable (≥0 mg), where higher values indicate greater opioid consumption (worse outcome).

Perioperative/Periprocedural; 3 months postoperatively
Postoperative Medical Complications
기간: Perioperative/Periprocedural

Postoperative Medical Complications:

Occurrence of medical complications following primary total knee arthroplasty, including myocardial infarction, venous thromboembolism, cerebrovascular accident, acute kidney injury, respiratory failure, urinary tract infection, pneumonia, gastrointestinal obstruction, and need for intensive care unit (ICU) admission during the same hospitalization. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.

Perioperative/Periprocedural
Postoperative Surgical Complications
기간: Perioperative/Periprocedural; 3 months postoperatively
Occurrence of surgical complications following primary total knee arthroplasty, including reoperation, periprosthetic fracture, dislocation, infection, and postoperative stiffness. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.
Perioperative/Periprocedural; 3 months postoperatively

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Nicholas M Hernandez, MD, University of Washington

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 1일

기본 완료 (추정된)

2028년 6월 1일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2026년 5월 1일

QC 기준을 충족하는 최초 제출

2026년 5월 13일

처음 게시됨 (실제)

2026년 5월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 13일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Doxepin 6 mg에 대한 임상 시험

구독하다